

# Cabinet Briefing — Longevity Platform Grant

Marschall S. Runge, M.D., Ph.D. — Proposal architect / originating author<sup>1</sup>, Steven L. Kunkel, Ph.D. (proposed Principal Investigator)<sup>2</sup>, Brian D. Athey, Ph.D. (proposed co-Principal Investigator)<sup>3</sup>, Sachin Kheterpal, M.D., MBA<sup>4</sup>, Scott W. Ballinger, Ph.D.<sup>5</sup>, Ryan E. Mills, Ph.D.<sup>6</sup>, and Greg Farnum<sup>7</sup>

<sup>1</sup>Michigan Medicine, University of Michigan, Ann Arbor, MI

<sup>2</sup>Department of Pathology, University of Michigan

<sup>3</sup>Department of Computational Medicine and Bioinformatics, University of Michigan

<sup>4</sup>Multicenter Perioperative Outcomes Group (MPOG), University of Michigan

<sup>5</sup>Ellison Institute of Technology / Oracle Health (partnership)

May 12, 2026

## Executive Briefing — Living Longer, Living Better

### One-sentence summary

A multi-PI longevity proposal authored by EVP / CEO / Dean Marschall S. Runge that operationalizes “aging-genomics” — the natural extension of pharmacogenomics — as a closed-loop measure → model → intervene → re-measure platform deployable through Michigan Medicine, the Ellison Institute partnership, and Oracle Health.

### Strategic context

- **Market.** Longevity / healthspan is a fast-growing preventative-medicine market saturated with under-validated influencer-driven products. Rigorously-validated diagnostics + decision-support has no incumbent.
- **Michigan’s distinctive assets.** MGI (90K recontactable patients), MPOG (Kheterpal, 85+ hospitals, millions of records), Department of Computational Medicine & Bioinformatics, three decades of Runge-Ballinger mtDNA-atherogenesis work. No other institution combines these.
- **Partnership leverage.** Ellison Institute of Technology + Oracle Health provide population-scale data and compute (150M patient records) that no academic environment has internally.

### Funding strategy

The proposal supports submission to multiple mechanisms in parallel across NIH (R01, NIA R01, R21, P01, T32, U19 multi-PI center), federal agencies (ARPA-H, DARPA-BTO, NSF), investigator awards (HHMI, Buck, AFAR), and major philanthropic channels (Asteria, Impetus, Hevolution, Schmidt Futures, Open Philanthropy, Wellcome Leap, Hillblom, CPRIT).

A single content base auto-generates 26 different mechanism PDFs, plus a slide deck and conference poster, with a build pipeline that regenerates everything on every update. This means submitting to a new mechanism is hours, not weeks, of work.

## Recommended decisions for governance review

1. **First submission target.** NIA R01 (12 pages) is content- complete and aligned with NIA program review. Recommend approving this as the lead submission with NHLBI / NIGMS R01 as a parallel track.
2. **Multi-PI delegation.** Steven Kunkel as Principal Investigator, Brian Athey as co-Principal Investigator, with Sachin Kheterpal, Ryan Mills, Scott Ballinger, and Greg Farnum as named co-investigators. Marschall serves as architect, senior collaborator, and institutional sponsor.
3. **Partnership terms.** Confirm Ellison Institute MOU and Oracle Health 150M EHR access tier are sufficient to support the Aim 1 LCI external-validation analyses.
4. **Resource commitments.** Pre-clinical drug-screening capacity in Phase 2 (Years 4–6) and IVD diagnostic development partnership in Phase 3 (Years 7+) will require institutional commitment letters at submission time.

## Where to read more

Dashboard: [single-molecule-sequencing.github.io/longevity-platform-grant](https://single-molecule-sequencing.github.io/longevity-platform-grant). Marschall's two source drafts are linked at the top of the dashboard along with all 28 generated PDFs and a status grid showing what's authored vs. what needs PI input vs. what's blocked on partnership-governance terms.